Tenofovir amibufenamide in chronic hepatitis B: Lipid changes and 144-week safety with tenofovir disoproxil fumarate-to-tenofovir amibufenamide switch

doi:10.3748/wjg.v31.i26.109285

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 31, Issue 26

This Article

Academic Content and Language Evaluation of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Supplementary Materials of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (134)

All Articles published online

The chart showing PDF series, HTML series, Figures (1-4) series, Tables (1-5) series.

Item

Count

PDF

HTML

Figures (1-4)

Tables (1-5)

Sum=106

Publishing Process of This Article

The chart showing Browse series, Download series.

Item

Count

Browse

Download

Sum=19

Jul 14, 2025 (publication date) through Jul 12, 2025

Times Cited of This Article

Times Cited (0)

Journal Information of This Article

Publication Name

World Journal of Gastroenterology

ISSN

1007-9327

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Clinical Trials Study

World J Gastroenterol. Jul 14, 2025; 31(26): 109285
Published online Jul 14, 2025. doi: 10.3748/wjg.v31.i26.109285

Table 1 Baseline demographic profiles and characteristics, mean ± SE

Mark	Total (n = 53)	TDF (n = 14)	TMF (n = 39)	P value
Gender (M/F)	36/17	8/6	28/11	0.314
Age	36.89 ± 1.44	34.50 ± 1.95	37.74 ± 1.83	0.327
BMI 0 week	22.83 ± 0.67	22.01 ± 1.02	23.16 ± 0.85	0.448
WBC 0 week	6.13 ± 0.22	6.27 ± 0.45	6.08 ± 0.26	0.715
Hb 0 week	149.02 ± 2.06	147.79 ± 3.88	149.46 ± 2.45	0.723
PLT 0 week	214.62 ± 10.01	234.00 ± 15.58	207.67 ± 12.31	0.250
ALT 0 week	129.10 ± 17.09	176.42 ± 53.02	112.12 ± 13.01	0.097
AST 0 week	79.79 ± 9.70	99.85 ± 28.31	73.10 ± 8.91	0.236
Cr 0 week	65.84 ± 2.08	67.25 ± 5.17	65.37 ± 2.22	0.699
CLCR 0 week	116.45 ± 3.46	112.04 ± 7.11	117.91 ± 3.98	0.468
PHOS 0 week	1.06 ± 0.03	1.09 ± 0.07	1.05 ± 0.03	0.459
GLU 0 week	4.97 ± 0.11	4.73 ± 0.11	5.06 ± 0.14	0.176
TG 0 week	1.06 ± 0.07	1.15 ± 0.20	1.03 ± 0.06	0.477
CHOL 0 week	4.76 ± 0.15	4.77 ± 0.20	4.76 ± 0.19	0.984
HDL 0 week	1.46 ± 0.05	1.45 ± 0.10	1.46 ± 0.06	0.960
LDL 0 week	2.74 ± 0.11	2.74 ± 0.17	2.74 ± 0.14	0.989
FIB-4 0 week	1.46 ± 0.18	1.28 ± 0.29	1.52 ± 0.22	0.576
CAP 0 week	204.50 ± 5.74	212.07 ± 13.44	201.38 ± 5.99	0.403
RNA 0 week	4.14 ± 0.39	3.99 ± 0.86	4.18 ± 0.44	0.845
DNA 0 week	6.81 ± 0.17	7.20 ± 0.28	6.67 ± 0.21	0.181
miR3 0 week	5.38 ± 0.29	5.33 ± 0.60	5.40 ± 0.34	0.919
HBsAg 0 week	2.94 ± 0.12	3.12 ± 0.25	2.88 ± 0.14	0.381
HBeAg 0 week	0.98 ± 0.27	1.33 ± 0.54	0.85 ± 0.31	0.441

TMF: Tenofovir amibufenamide; TDF: Tenofovir disoproxil fumarate; M: Male; F: Female; BMI: Body mass index; WBC: White blood cells; Hb: Hemoglobin; PLT: Platelet; ALT: Alanine aminotransferase; AST: Aspartate aminotransferase; Cr: Creatinine; CLCR: Creatinine clearance; PHOS: Phosphorus; GLU: Glucose; TG: Triglycerides; CHOL: Cholesterol; HDL: High-density lipoprotein; LDL: Low-density lipoprotein; FIB-4: Fibrosis-4; CAP: C-reactive protein; HBsAg: Hepatitis B surface antigen; HBeAg: Hepatitis B e antigen; miR3: Hepatitis B virus-microRNA-3.

Table 2 Comparison within the tenofovir amibufenamide group after treatment, mean ± SE

TMF	0 week	96 weeks	(0 week vs 96 weeks)
WBC	6.08 ± 0.26	6.53 ± 0.28	0.247149198
Hb	149.46 ± 2.45	149.21 ± 2.78	0.944983486
PLT	207.67 ± 12.31	213.10 ± 11.67	0.74947324
ALT	112.12 ± 13.01	23.48 ± 2.31	3.09 × 10^-9
AST	73.10 ± 8.91	23.22 ± 1.21	4.05 × 10^-7
Cr	65.37 ± 2.22	74.05 ± 2.12	0.006031745
CLCR	117.91 ± 3.98	100.63 ± 3.44	0.001543066
PHOS	1.05 ± 0.03	0.88 ± 0.02	1.82 × 10^-5
GLU	5.06 ± 0.14	5.65 ± 0.42	0.186321806
TG	1.03 ± 0.06	1.29 ± 0.13	0.069367579
CHOL	4.76 ± 0.19	4.64 ± 0.14	0.613234644
HDL	1.46 ± 0.06	1.37 ± 0.07	0.35635419
LDL	2.74 ± 0.14	2.95 ± 0.13	0.276270192
FIB-4	1.52 ± 0.22	1.28 ± 0.24	0.475793108
CAP	201.38 ± 5.99	202.80 ± 6.26	0.870684054
miR3	5.40 ± 0.34	2.41 ± 0.42	4.27 × 10^-7
RNA	4.18 ± 0.44	0.53 ± 0.23	5.19 × 10^-10
DNA	6.67 ± 0.21	0.27 ± 0.16	1.69 × 10^-28
HBsAg	2.88 ± 0.14	2.94 ± 0.10	0.696890055
HBeAg	0.85 ± 0.31	-0.15 ± 0.18	0.005855419

TMF: Tenofovir amibufenamide; WBC: White blood cells; Hb: Hemoglobin; PLT: Platelet; ALT: Alanine aminotransferase; AST: Aspartate aminotransferase; Cr: Creatinine; CLCR: Creatinine clearance; PHOS: Phosphorus; GLU: Glucose; TG: Triglycerides; CHOL: Cholesterol; HDL: High-density lipoprotein; LDL: Low-density lipoprotein; FIB-4: Fibrosis-4; CAP: C-reactive protein; HBsAg: Hepatitis B surface antigen; HBeAg: Hepatitis B e antigen; miR3: Hepatitis B virus-microRNA-3.

Table 3 Comparison within the tenofovir disoproxil fumarate group after treatment, mean ± SE

TDF	0 week	96 weeks	(0 week vs 96 weeks)
WBC	6.27 ± 0.45	6.87 ± 0.63	0.443861557
Hb	147.79 ± 3.88	147.50 ± 5.80	0.967641272
PLT	234.00 ± 15.58	239.14 ± 11.38	0.791953625
ALT	176.42 ± 53.02	20.62 ± 3.63	0.00922277
AST	99.85 ± 28.31	22.75 ± 1.15	0.011908537
Cr	67.25 ± 5.17	77.49 ± 5.63	0.192832703
CLCR	112.04 ± 7.11	90.04 ± 6.85	0.036435267
PHOS	1.09 ± 0.07	1.23 ± 0.27	0.611661657
GLU	4.73 ± 0.11	4.77 ± 0.14	0.80941735
TG	1.15 ± 0.20	2.42 ± 1.32	0.332101848
CHOL	4.77 ± 0.20	3.97 ± 0.19	0.008550427
HDL	1.45 ± 0.10	1.14 ± 0.10	0.033296713
LDL	2.74 ± 0.17	2.23 ± 0.17	0.046729094
FIB-4	1.28 ± 0.29	1.12 ± 0.39	0.742777384
CAP	212.07 ± 13.44	185.17 ± 6.02	0.09703147
miR3	5.33 ± 0.60	2.35 ± 0.69	0.003107141
RNA	3.99 ± 0.86	1.29 ± 0.68	0.024764947
DNA	7.20 ± 0.28	0.29 ± 0.29	4.24 × 10^-12
HBsAg	3.12 ± 0.25	2.92 ± 0.13	0.473322675
HBeAg	1.33 ± 0.54	-0.03 ± 0.32	0.040841537

TDF: Tenofovir disoproxil fumarate; WBC: White blood cells; Hb: Hemoglobin; PLT: Platelet; ALT: Alanine aminotransferase; AST: Aspartate aminotransferase; Cr: Creatinine; CLCR: Creatinine clearance; PHOS: Phosphorus; GLU: Glucose; TG: Triglycerides; CHOL: Cholesterol; HDL: High-density lipoprotein; LDL: Low-density lipoprotein; FIB-4: Fibrosis-4; CAP: C-reactive protein; HBsAg: Hepatitis B surface antigen; HBeAg: Hepatitis B e antigen; miR3: Hepatitis B virus-microRNA-3.

Table 4 Comparison of laboratory finding at 96 weeks in tenofovir disoproxil fumarate/tenofovir amibufenamide groups, mean ± SE

96 weeks	TDF	TMF	P value
WBC	6.87 ± 0.63	6.53 ± 0.28	0.578
Hb	147.50 ± 5.80	149.21 ± 2.78	0.769
PLT	239.14 ± 11.38	213.10 ± 11.67	0.214
ALT	20.62 ± 3.63	23.48 ± 2.31	0.531
AST	22.75 ± 1.15	23.22 ± 1.21	0.830
Cr	77.49 ± 5.63	74.05 ± 2.12	0.485
CLCR	90.04 ± 6.85	100.63 ± 3.44	0.152
PHOS	1.23 ± 0.27	0.88 ± 0.02	0.026
GLU	4.77 ± 0.14	5.65 ± 0.42	0.236
TG	2.42 ± 1.32	1.29 ± 0.13	0.163
CHOL	3.97 ± 0.19	4.64 ± 0.14	0.011
HDL	1.14 ± 0.10	1.37 ± 0.07	0.077
LDL	2.23 ± 0.17	2.95 ± 0.13	0.005
FIB-4	1.12 ± 0.39	1.28 ± 0.24	0.739
CAP	185.17 ± 6.02	202.80 ± 6.26	0.105
miR3	2.35 ± 0.69	2.41 ± 0.42	0.937
RNA	1.29 ± 0.68	0.53 ± 0.23	0.186
DNA	0.29 ± 0.29	0.27 ± 0.16	0.936
HBsAg	2.92 ± 0.13	2.94 ± 0.10	0.874
HBeAg	-0.03 ± 0.32	-0.15 ± 0.18	0.724

TMF: Tenofovir amibufenamide; TDF: Tenofovir disoproxil fumarate; WBC: White blood cells; Hb: Hemoglobin; PLT: Platelet; ALT: Alanine aminotransferase; AST: Aspartate aminotransferase; Cr: Creatinine; CLCR: Creatinine clearance; PHOS: Phosphorus; GLU: Glucose; TG: Triglycerides; CHOL: Cholesterol; HDL: High-density lipoprotein; LDL: Low-density lipoprotein; FIB-4: Fibrosis-4; CAP: C-reactive protein; HBsAg: Hepatitis B surface antigen; HBeAg: Hepatitis B e antigen; miR3: Hepatitis B virus-microRNA-3.

Table 5 Comparison of laboratory finding at 144 weeks in tenofovir disoproxil fumarate to tenofovir amibufenamide / tenofovir disoproxil fumarate groups

144 weeks	TDF to TMF	TMF	P value
WBC	6.20 ± 0.37	6.48 ± 0.27	0.558
Hb	145.57 ± 4.64	148.31 ± 2.92	0.764
PLT	240.50 ± 12.49	224.31 ± 12.05	0.405
ALT	32.71 ± 10.93	28.27 ± 5.24	0.257
AST	24.91 ± 3.67	25.01 ± 2.14	0.845
Cr	72.38 ± 4.95	74.26 ± 2.26	0.414
CLCR	103.07 ± 6.79	101.33 ± 3.50	0.154
PHOS	1.01 ± 0.04	0.97 ± 0.03	0.485
GLU	5.15 ± 0.17	5.82 ± 0.36	0.887
TG	1.56 ± 0.38	1.34 ± 0.14	0.904
CHOL	4.64 ± 0.23	4.47 ± 0.16	0.561
HDL	1.29 ± 0.12	1.29 ± 0.06	0.937
LDL	2.83 ± 0.22	2.78 ± 0.13	0.220
FIB-4	15.38 ± 14.59	1.08 ± 0.13	0.739
CAP	182.22 ± 9.02	189.22 ± 7.8	0.175
miR3	2.27 ± 0.72	2.62 ± 0.44	0.896
RNA	1.46 ± 0.79	0.51 ± 0.25	0.986
DNA	1.24 ± 0.76	0.56 ± 0.33	0.531
HBsAg	3.16 ± 0.17	2.95 ± 0.10	0.849
HBeAg	0.18 ± 0.39	-0.37 ± 0.18	0.865

Citation: Zeng ZH, Liu JQ, Zhang M, Qiu CL, Xu ZY. Tenofovir amibufenamide in chronic hepatitis B: Lipid changes and 144-week safety with tenofovir disoproxil fumarate-to-tenofovir amibufenamide switch. World J Gastroenterol 2025; 31(26): 109285
URL: https://www.wjgnet.com/1007-9327/full/v31/i26/109285.htm
DOI: https://dx.doi.org/10.3748/wjg.v31.i26.109285